Charles River Laboratories (CRL) Tops Q2 EPS by 2c; Lowers Outlook

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.77, $0.02 better than the analyst estimate of $2.75. Revenue for the quarter came in at $973.1 million versus the consensus estimate of $997.96 million.

GUIDANCE:

Charles River Laboratories sees FY2022 EPS of $10.70-$10.95, versus the consensus of $11.53. Sees revenue up 9-11% versus prior of 13.5-15.5%.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Intercontinental Exchange (ICE) PT Lowered to $208 at Raymond James, 'we view the risk/reward as attractive'
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion